A Retrospective Analysis of Mortality in Subjects Who Participated in 3 Studies of Galantamine in Mild Cognitive Impairment.
Phase of Trial: Phase III
Latest Information Update: 11 Apr 2012
At a glance
- Drugs Galantamine (Primary)
- Indications Mild cognitive impairment
- Focus Adverse reactions
- Sponsors Janssen Research & Development
- 11 Apr 2012 Actual patient number changed from 2058 to 1083 as reported by ClinicalTrials.gov.
- 11 Apr 2012 Additional trial locations identified as reported by ClinicalTrials.gov.
- 15 Aug 2008 New trial record.